Research progresses of 99Tcm-3PRGD2 and 99Tcm-MIBI for diagnosis and treatment of differentiated thyroid cancer
10.13929/j.issn.1003-3289.2025.10.035
- VernacularTitle:99Tcm-3PRGD2和99Tcm-MIBI用于诊断与治疗分化型甲状腺癌研究进展
- Author:
Yonghao LI
1
;
Jiangyan LIU
1
;
Zhengcun CUI
1
Author Information
1. 兰州大学第二医院核医学科,甘肃兰州 730030
- Publication Type:Journal Article
- Keywords:
thyroid neoplasms;
radionuclide imaging;
organotechnetium compounds
- From:
Chinese Journal of Medical Imaging Technology
2025;41(10):1768-1771
- CountryChina
- Language:Chinese
-
Abstract:
Differentiated thyroid cancer(DTC)accounts for more than 95％of all thyroid cancers.99Tcm-3PRGD2 can specifically bind to integrin αvβ3 receptors highly expressed on the surfaces of neovascular endothelial cells and tumor cells in malignant tumors.With high specificity and safety,99Tcm-3PRGD2 can not only be used for diagnosing DTC and its metastases,but also evaluating the efficacy of anti-angiogenic and anti-αvβ3 therapies.99Tcm-MIBI is a non-specific tumor-avid imaging agent,which may improve diagnostic accuracy combined with 99Tcm-3PRGD2.The research progresses of 99Tcm-3PRGD2 and 99Tcm-MIBI for diagnosis and treatment of DTC were reviewed in this article.
